comparison cohort) who were the same age, race, and gender were identified and matched. A random index date was chosen to minimize selection bias. Patients in both cohorts were required to be at least age 18 years, with continuous medical and pharmacy benefits 1-year pre-and 1-year post-index date. One-to-one propensity score matching (PSM) was used to compare health care costs and utilizations during the follow-up period, between the diseased and comparison cohorts, and adjusted for baseline demographic and clinical characteristics. Results: After risk adjustment by PSM, a total of 19,079 patients in each cohort were matched. Significantly more breast cancer patients had inpatient admissions (23.77% vs. 12.56%, p< 0.0001) and long-term care (7.77% vs. 6.60%, p< 0.0001), other service (99.88% vs. 87.86%, p< 0.0001) and pharmacy visits (77.80% vs. 68.85%, p< 0.0001), compared to those without breast cancer. Breast cancer patients also incurred significantly higher inpatient ($2,141 vs. $1,537, p< 0.0001), long-term care ($7,471 vs. $5,335, p< 0.0001), other service visit ($23,592 vs. $14,780, p< 0.0001) and pharmacy costs ($3,379 vs. $2,787, p< 0.0001) compared to those in the comparison cohort. ConClusions: Breast cancer patients in the Medicaid program incurred substantially higher health care resource utilization and costs compared to those without the disease.